

PACE/PAP/CRDP Provider Bulletin

February 14, 2023

Commonwealth of Pennsylvania Drug Manufacturers' Rebate Program Non-Participating Manufacturer

Effective March 31, 2023:

GSK has notified PACE, PAP and CRDP that they will be terminating their participation in the Commonwealth's rebate program.

Labeler codes being terminated include: 00007,00145, 00173

Below are some of the medications that will no longer be reimbursed by PACE:

00007	Coreg, Coreg CR
00145	Veltin, Brevoxyl, Clindets, Lacticare, Panoxyl, Sarna, Zeasorb
00173	Flovent, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta

Correspondence is being prepared to notify prescribers that PACE will no longer provide reimbursement for GSK medications, and they may need to consider alternative therapies for their patients.

GSK offers programs for patients that meet income and other eligibility requirements. Members of the PACE and CRDP Programs that are affected by the termination may access [GSKForYou | GSK Patient Assistance Program](#) for additional information on these programs.

Should you have any additional questions please contact Provider Services at 1-800-835-4080.